Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue ...

Exact Sciences shares plunged Wednesday after the company reported widening losses. The maker of the Cologuard colon cancer screening test lowered its full-year outlook. CEO Kevin Conroy said the ...

Exact Sciences is unprofitable, and its most important product faces new competition. But the new, just-launched version of its Cologuard test could spur top-line growth. The improved cancer ...

Exact Sciences' Q3 earnings report has led to a ... Exact's main sources of revenues are its Cologuard test, a "patient-friendly, non-invasive stool-based DNA screening test that utilizes a ...

This approach contributed to strong growth in Cologuard test utilization among rescreen patients and within care gap programs during the third quarter. Exact Sciences received FDA approval for the ...

At this time, I would like to welcome everyone to the Exact Sciences third-quarter 2024 ... including a record number with Cologuard and Oncotype DX, growing total revenue 13% year over year ...

What's going on with Exact Sciences? Exact Sciences is best known for Cologuard, its at-home, non-invasive stool test for colorectal cancer. The company has helped screen millions of eligible ...

Equities are still in a bull run. The S&P 500 is up by 22% so far in 2024. Not every company has come along for the ride, though. Exact Sciences (NASDAQ: EXAS), a cancer-focused biotechnology ...